The possible neuroprotective effects of GLP-1 agonists on experimentally induced alzheimer’s disease in mice / (Record no. 176093)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05134namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251225115313.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251122s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.78 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.78 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.Ph.D.2025.No.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Norhan Nabil Mohammed El-Badawy, |
| Preparation | preparation. |
| 245 14 - TITLE STATEMENT | |
| Title | The possible neuroprotective effects of GLP-1 agonists on experimentally induced alzheimer’s disease in mice / |
| Statement of responsibility, etc. | by Norhan Nabil Mohammed El-Badawy ; Supervision of Prof. Dr. Noha Fawzy Abdelkader, Prof. Dr. Maha Ali Eissa Ahmed. |
| 246 ## - VARYING FORM OF TITLE | |
| Title proper/short title | التأثيرات المحتملة الواقية للأعصاب لمستضادات جي إل بي-1 فى مرض الزهايمر المحدث تجريبياً فى الفئران |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 121 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 94-121. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Tau hyper-phosphorylation has been recognized as an essential contributor to neurodegeneration in Alzheimer’s disease (AD) and related tauopathies. In the last decade, tau hyper-phosphorylation has gained considerable concern in AD therapeutic development. Tauopathies are manifested with a broad spectrum of symptoms, from dementia to cognitive decline and motor impairments. Tau undergoes conformational changes and abnormal phosphorylation that mediate its detaching from microtubules, forming neurofibrillary tangles (NFTs). In the current study, a widely used P301S transgenic mice model of tauopathy was employed to evaluate the possible neuroprotective effects of semaglutide as an autophagy regulator through modifications of the brain renin-angiotensin system (RAS). Mice were divided into two groups according to their genotypes (wild type (Wt) and P301S), which were further subdivided to receive either vehicle (saline) or semaglutide (25 nmol/kg, i.p.), once every 2 days for 28 days. Current data suggest that semaglutide ameliorated the hyperactive pattern and alleviated the cognitive decline of P301S mice. It also hastened the autophagic flux through augmenting angiotensin-converting enzyme 2/sirtuin 1/forkhead box protein O1 signaling. Semaglutide also hindered the expression of phosphorylated adenosine monophosphate-activated protein kinase and phosphorylated glycogen synthase kinase-3 beta at serine 9, reducing the propagation of neuroinflammatory cytokines and oxidative reactions. Finally, semaglutide protected against hippocampal degeneration and reduced the immunoreactivity for total tau and ionized calcium-binding adapter molecule. Semaglutide showed promising neuroprotective implications in alleviating tauopathy-related AD’s molecular and behavioral deficits through controlling autophagy and brain RAS. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | إن مرض الزهايمر هو أكثر أنواع التاوبيات انتشارا حيث يتميز بفقدان الخلايا العصبية وضمور الدماغ الشديد مما يؤدي إلى ظهور الخرف والعيوب الإدراكية. إن تراكم رواسب البروتين (أميلويد-بيتا و التاو) هو السمة المرضية المميزة لمرض الزهايمر. وتكمن عيوب الأدوية التقليدية المعتمدة لعلاج مرض الزهايمر في تخفيف الأعراض بشكل محدود وعدم قدرتها على معالجة السبب الفعلي أو تثبيط تقدم المرض. كما أن فشل الأدوية المضادة للأميلويد قد أبرز الحاجة إلى تطوير تدخلات علاجية جديدة تركز على علم الأمراض الناتج عن بروتين التاو لإعاقة أو تأجيل ظهور الخرف. إن نموذج الفئران بى 301 اس (P301S) يُستخدم على نطاق واسع لإعادة تجسيد أمراض التاو المرتبطة بمرض الزهايمر، وبالتالي تيسير إمكانية فهم ودمج خطوط علاجية جديدة تستهدف بشكل خاص تجمعات التاو وتشابكات التاو بروتين العصبية. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drugs that affect the nervous system |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الأدوية المؤثرة على الجهاز العصبى |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Tauopathy |
| -- | Alzheimer's disease |
| -- | Semaglutide |
| -- | Autophagy |
| -- | ACE2/SIRT1/FOXO1 |
| -- | Microglia Polarization |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noha Fawzy Abdelkader |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maha Ali Eissa Ahmed |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Noha Fawzy Abdelkader |
| -- | Maha Ali Eissa Ahmed |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology & Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 22.11.2025 | 92657 | Cai01.08.09.Ph.D.2025.No.P | 01010110092657000 | 22.11.2025 | 22.11.2025 | Thesis |